FibroGen’s anemia pill falls short in blood cancer study

An anemia pill from FibroGen didn’t help patients with a type of bone marrow cancer stop receiving blood transfusions in a Phase 3 trial, the latest setback for a drug that approved internationally but rejected in the U.S.